- Home
- STG vs MDXH Comparison
STG vs MDXH Comparison
Compare STG & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STG | MDXH |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 167.8M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STG | MDXH |
|---|---|---|
| Price | $5.82 | $3.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 8.5K | ★ 182.7K |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $285,589,112.00 | $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | $1.45 | ★ N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $4.28 | $1.35 |
| 52 Week High | $15.00 | $5.33 |
Technical Indicators
Market Signals| Indicator | STG | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 34.99 |
| Support Level | $5.50 | $3.31 |
| Resistance Level | $6.00 | $3.74 |
| Average True Range (ATR) | 0.33 | 0.18 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 84.51 | 8.65 |
Price Performance
Historical ComparisonAbout STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.